04:17 AM EDT, 06/02/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Friday that the phase III trial of its immunotherapy, Imfinzi, when used before and after surgery with chemotherapy, showed significant improvement in event-free survival in patients with gastric and gastroesophageal junction cancers.

The company said the study showed patients treated with its neoadjuvant Imfinzi in combination with chemotherapy had a 29% lower risk of disease progression, recurrence, or death compared to chemotherapy alone.

At one year, 78.2% of patients on the Imfinzi regimen were event-free versus 74% with standard care; at two years, 67.4% remained event-free versus 58.5%, the company said, adding that estimated median event-free survival had not yet been reached for its therapy compared with 32.8 months for the comparator arm.

Overall survival results are still pending but show a positive trend so far, it added.